


## MATERIAL DE APOIO:

Tratamento neoadjuvante do câncer de mama com super-expressão de HER2**1. LINK DE ACESSO AOS PRINCIPAIS ESTUDOS**


	<b>PRIMEIROS ESTUDOS, REVISÕES, META-ANÁLISE.</b>
Z1041	<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176878/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176878/</a>
NOAH	<a href="https://pubmed.ncbi.nlm.nih.gov/24657003/">https://pubmed.ncbi.nlm.nih.gov/24657003/</a>
COCHRANE	<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718210/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718210/</a>
META-ANÁLISE	<a href="https://pubmed.ncbi.nlm.nih.gov/26914222/">https://pubmed.ncbi.nlm.nih.gov/26914222/</a>
REVISÃO	<a href="https://pubmed.ncbi.nlm.nih.gov/31839166/">https://pubmed.ncbi.nlm.nih.gov/31839166/</a>
	<b>DUPLO BLOQUEIO COM LAPATINIBE</b>
NSABP B41	<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797698/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797698/</a>
CALGB 40601	<a href="https://pubmed.ncbi.nlm.nih.gov/26527775/">https://pubmed.ncbi.nlm.nih.gov/26527775/</a>
GEPARQUINTO	<a href="https://pubmed.ncbi.nlm.nih.gov/22257523/">https://pubmed.ncbi.nlm.nih.gov/22257523/</a>
NeoALTTO	<a href="https://pubmed.ncbi.nlm.nih.gov/31377477/">https://pubmed.ncbi.nlm.nih.gov/31377477/</a>
	<b>DUPLO BLOQUEIO COM PERTUZUMABE</b>
BERENICE	<a href="https://pubmed.ncbi.nlm.nih.gov/29253081/">https://pubmed.ncbi.nlm.nih.gov/29253081/</a>
KRISTINE	<a href="https://pubmed.ncbi.nlm.nih.gov/31157583/">https://pubmed.ncbi.nlm.nih.gov/31157583/</a>
NEOSPHERE	<a href="https://pubmed.ncbi.nlm.nih.gov/22153890/">https://pubmed.ncbi.nlm.nih.gov/22153890/</a>
TRYPHAENA	<a href="https://www.annalsofoncology.org/article/S0923-7534(19)36929-7/fulltext">https://www.annalsofoncology.org/article/S0923-7534(19)36929-7/fulltext</a>
	<b>ADJUVÂNCIA APÓS RESPOSTA PARCIAL A NEOADJUVÂNCIA</b>
KATHERINE	<a href="https://pubmed.ncbi.nlm.nih.gov/30516102/">https://pubmed.ncbi.nlm.nih.gov/30516102/</a>
	<b>DESCALONAMENTO DE TRATAMENTO</b>
PHERGAIN	<a href="https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.503">https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.503</a>
TRAIN-2	<a href="https://pubmed.ncbi.nlm.nih.gov/30413379/">https://pubmed.ncbi.nlm.nih.gov/30413379/</a>

### 2. Estudos mais relevantes para a prática clínica:


#### I - NeoSphere – estudo fase II, multicêntrico, randomizado, open-label




#### II - TRYPHAENA - Estudo fase II, randomizado



### III – TRAIN 2 – Estudo fase III, randomizado, open-label



### IV – KATHERINE – Estudo fase III, randomizado, open-label



TDM1 X Trazuzumabe		HR	p
Endpoint Primário	SLDI	0,1	<0,001
Endpoint Secundário	SG	0,7	0,08

Carolina Rutkowski  
 Oncologia Clínica  
[carolinarutkowski@yahoo.com.br](mailto:carolinarutkowski@yahoo.com.br)  
 31-992392479

Tell me and I forget  
 Teach me and I remember  
 Involve me and I learn  
 Benjamin Franklin